Differential HCC risk among HBV indeterminate types at baseline and by phase transition.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: chronic hepatitis B (CHB) with indeterminate phase make up a diverse cohort with likely different outcomes
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Several types of indeterminate CHB had high HCC risk. These data support the potential expansion of treatment criteria for higher risk types of indeterminate CHB.
[BACKGROUND] Patients with chronic hepatitis B (CHB) with indeterminate phase make up a diverse cohort with likely different outcomes.
- p-value p<0.001
- 연구 설계 cohort study
APA
Huang R, Trinh HN, et al. (2025). Differential HCC risk among HBV indeterminate types at baseline and by phase transition.. Gut, 74(11), 1873-1882. https://doi.org/10.1136/gutjnl-2025-335033
MLA
Huang R, et al.. "Differential HCC risk among HBV indeterminate types at baseline and by phase transition.." Gut, vol. 74, no. 11, 2025, pp. 1873-1882.
PMID
40467102
Abstract
[BACKGROUND] Patients with chronic hepatitis B (CHB) with indeterminate phase make up a diverse cohort with likely different outcomes.
[OBJECTIVE] We compared the hepatocellular carcinoma (HCC) risk in indeterminate CHB with different baseline types and by phase transition.
[DESIGN] This was a retrospective cohort study of 1986 (94.2% Asian) patients with indeterminate CHB from nine countries/regions. Patients were classified according to baseline hepatitis B e-antigen (HBeAg), alanine aminotransferase (ALT) and HBV DNA. The cumulative HCC incidence was compared.
[RESULTS] Based on the 2018 American Association for the Study of Liver Disease guidance, most indeterminate patients were HBeAg negative (84.9%). The 20-year HCC incidence was highest in type 1 (HBeAg positive, ALT<1×upper limit of normal (ULN), HBV DNA 20 000-10 IU/mL, 36.2%) and lowest in type 8 (HBeAg negative, ALT 1-2×ULN, HBV DNA<2000 IU/mL, 1.9%). The 20-year HCC incidence of those who remained indeterminate was 4.7%. Cumulative HCC incidence rates were high in patients with indeterminate CHB who transitioned to immune tolerant (15 years: 16.5%) or immune active (20 years: 13.7%) phase but low for those who transitioned to immune inactive phase (20 years: 2.5%). In multivariable analysis, compared with type 8, higher HCC risk was seen with HBeAg-positive type 1 (adjusted HR (aHR)=40.1, p<0.001), type 2 (ALT 1-2×ULN, HBV DNA≥20 000 IU/mL, aHR=25.1, p<0.001), HBeAg-negative type 9 (ALT>2×ULN, HBV DNA<2000 IU/mL, aHR=4.6, p=0.032) and type 10 (ALT<1×ULN, HBV DNA<2000 IU/mL but with moderate to severe inflammation/fibrosis, aHR=7.3, p=0.033). Similar directions in HCC risks were found in analyses based on the 2017 European Association for the Study of the Liver guideline.
[CONCLUSION] Several types of indeterminate CHB had high HCC risk. These data support the potential expansion of treatment criteria for higher risk types of indeterminate CHB.
[OBJECTIVE] We compared the hepatocellular carcinoma (HCC) risk in indeterminate CHB with different baseline types and by phase transition.
[DESIGN] This was a retrospective cohort study of 1986 (94.2% Asian) patients with indeterminate CHB from nine countries/regions. Patients were classified according to baseline hepatitis B e-antigen (HBeAg), alanine aminotransferase (ALT) and HBV DNA. The cumulative HCC incidence was compared.
[RESULTS] Based on the 2018 American Association for the Study of Liver Disease guidance, most indeterminate patients were HBeAg negative (84.9%). The 20-year HCC incidence was highest in type 1 (HBeAg positive, ALT<1×upper limit of normal (ULN), HBV DNA 20 000-10 IU/mL, 36.2%) and lowest in type 8 (HBeAg negative, ALT 1-2×ULN, HBV DNA<2000 IU/mL, 1.9%). The 20-year HCC incidence of those who remained indeterminate was 4.7%. Cumulative HCC incidence rates were high in patients with indeterminate CHB who transitioned to immune tolerant (15 years: 16.5%) or immune active (20 years: 13.7%) phase but low for those who transitioned to immune inactive phase (20 years: 2.5%). In multivariable analysis, compared with type 8, higher HCC risk was seen with HBeAg-positive type 1 (adjusted HR (aHR)=40.1, p<0.001), type 2 (ALT 1-2×ULN, HBV DNA≥20 000 IU/mL, aHR=25.1, p<0.001), HBeAg-negative type 9 (ALT>2×ULN, HBV DNA<2000 IU/mL, aHR=4.6, p=0.032) and type 10 (ALT<1×ULN, HBV DNA<2000 IU/mL but with moderate to severe inflammation/fibrosis, aHR=7.3, p=0.033). Similar directions in HCC risks were found in analyses based on the 2017 European Association for the Study of the Liver guideline.
[CONCLUSION] Several types of indeterminate CHB had high HCC risk. These data support the potential expansion of treatment criteria for higher risk types of indeterminate CHB.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Male; Hepatitis B, Chronic; Female; Retrospective Studies; Hepatitis B e Antigens; Middle Aged; Incidence; Adult; Alanine Transaminase; DNA, Viral; Hepatitis B virus; Risk Factors
같은 제1저자의 인용 많은 논문 (5)
- miR-596 as a novel prognostic biomarker and tumor suppressor in breast cancer through targeting EIF5AL1.
- Combining AI to reveal CCDC3-mediated pathways of colorectal cancer liver metastasis.
- Kaixuan Qibi granules attenuate myocardial fibrosis through BRD4 blockade regulated by the NF-κB/NLRP3 signaling pathway.
- Pretreatment emotional distress and peripheral biomarkers predict immune checkpoint inhibitor response in people with advanced inoperable gastroesophageal cancer.
- Correspondence to editorial 2 on "Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues".